Zynex announces first enrollments in apheresis donation clinical trial with second generation fluid monitoring system

Englewood, colo. , aug. 15, 2022 /prnewswire/ -- zynex, inc. (nasdaq: zyxi), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has started enrollments in an ongoing apheresis clinical trial with its second-generation fluid monitoring system, the cm-1600.
ZYXI Ratings Summary
ZYXI Quant Ranking